Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal

Retrovirology

Kristina Abel²  David Montefiori⁵  Donald N Forthal¹  Walid Heneine³  Don R Canfield⁴  Ross P Tarara⁴  Jonathan Lipscomb³  Gary Landucci¹  Jeffrey A Johnson³  Celia C LaBranche⁵  Yongzhi Geng⁴  Kartika Jayashankar⁴  Kristin A Trott⁴  Koen K A Van Rompay⁴ 

[1] Division of Infectious Diseases, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA, 92697, USA;Department of Microbiology and Immunology, School of Medicine, University of North Carolina, Chapel Hill, NC, 27599, USA;Division of HIV/AIDS Prevention, National Center for HIV, STD and Tuberculosis Prevention, Centers for Disease control and Prevention, Atlanta, GE, 30333, USA;California National Primate Research Center, University of California, Davis, CA, 95616, USA;Department of Surgery, Duke University, Durham, NC, 27710, USA

关键词: HIV;    Antiretroviral;    Functional cure;    SIV;    PMPA;    Tenofovir;   

Others  :  1209285
DOI  :  10.1186/1742-4690-9-57

 received in 2012-02-23, accepted in 2012-07-17,  发布年份 2012

【 摘 要 】

Background

We reported previously that while prolonged tenofovir monotherapy of macaques infected with virulent simian immunodeficiency virus (SIV) resulted invariably in the emergence of viral mutants with reduced in vitro drug susceptibility and a K65R mutation in reverse transcriptase, some animals controlled virus replication for years. Transient CD8+ cell depletion or short-term tenofovir interruption within 1 to 5 years of treatment demonstrated that a combination of CD8+ cell-mediated immune responses and continued tenofovir therapy was required for sustained suppression of viremia. We report here follow-up data on 5 such animals that received tenofovir for 8 to 14 years.

Results

Although one animal had a gradual increase in viremia from 3 years onwards, the other 4 tenofovir-treated animals maintained undetectable viremia with occasional viral blips (≤ 300 RNA copies/ml plasma). When tenofovir was withdrawn after 8 to 10 years from three animals with undetectable viremia, the pattern of occasional episodes of low viremia (≤ 3600 RNA/ml plasma) continued throughout the 10-month follow-up period. These animals had low virus levels in lymphoid tissues, and evidence of multiple SIV-specific immune responses.

Conclusion

Under certain conditions (i.e., prolonged antiviral therapy initiated early after infection; viral mutants with reduced drug susceptibility) a virus-host balance characterized by strong immunologic control of virus replication can be achieved. Although further research is needed to translate these findings into clinical applications, these observations provide hope for a functional cure of HIV infection via immunotherapeutic strategies that boost antiviral immunity and reduce the need for continuous antiretroviral therapy.

【 授权许可】

   
2012 Van Rompay et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372:293-299.
• [2]Cohen J: The emerging race to cure HIV infections. Science 2011, 332:784-785. 787–789
• [3]Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ: The challenge of finding a cure for HIV infection. Science 2009, 323:1304-1307.
• [4]Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW, Chomont N: HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010, 329:174-180.
• [5]Garcia F, Routy JP: Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29:6454-6463.
• [6]Paton NI: Treatment interruption strategies: how great are the risks? Curr Opin Infect Dis 2008, 21:25-30.
• [7]Autran B, Kinloch-de Loes S, Katlama C: Therapeutic immunization in HIV infection. Curr Opin HIV AIDS 2006, 1:323-329.
• [8]Rosenberg ES, Graham BS, Chan ES, Bosch RJ, Stocker V, Maenza J, Markowitz M, Little S, Sax PE, Collier AC, et al.: Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010, 5:e10555.
• [9]Van Rompay KK: Evaluation of antiretrovirals in animal models of HIV infection. Antivir Res 2010, 85:159-175.
• [10]Van Rompay KKA, Singh RP, Pahar B, Sodora DL, Wingfield C, Lawson JR, Marthas ML, Bischofberger N: CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 2004, 78:5324-5337.
• [11]Van Rompay KK, Johnson JA, Blackwood EJ, Singh RP, Lipscomb J, Matthews TB, Marthas ML, Pedersen NC, Bischofberger N, Heneine W, North TW: Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 2007, 4:25. BioMed Central Full Text
• [12]Van Rompay KKA, Cherrington JM, Marthas ML, Berardi CJ, Mulato AS, Spinner A, Tarara RP, Canfield DR, Telm S, Bischofberger N, Pedersen NC: 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996, 40:2586-2591.
• [13]Van Rompay KKA, Cherrington JM, Marthas ML, Lamy PD, Dailey PJ, Canfield DR, Tarara RP, Bischofberger N, Pedersen NC: 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother 1999, 43:802-812.
• [14]Van Rompay KKA, Brignolo LL, Meyer DJ, Jerome C, Tarara R, Spinner A, Hamilton M, Hirst LL, Bennett DR, Canfield DR, et al.: Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004, 48:1469-1487.
• [15]Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, et al.: Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008, 52:3144-3160.
• [16]Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI: Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology 2006, 3:97. BioMed Central Full Text
• [17]Van Rompay KKA, Miller MD, Marthas ML, Margot NA, Dailey PJ, Tarara RP, Canfield DR, Cherrington JM, Aguirre NL, Bischofberger N, Pedersen NC: Prophylactic and therapeutic benefits of short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol 2000, 74:1767-1774.
• [18]Boyer JD, Kumar S, Robinson T, Parkinson R, Wu L, Lewis M, Watkins DI, Weiner DB: Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response. J Med Primatol 2006, 35:202-209.
• [19]Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM, et al.: Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81:8827-8832.
• [20]Yant LJ, Friedrich TC, Johnson RC, May GE, Maness NJ, Enz AM, Lifson JD, O'Connor DH, Carrington M, Watkins DI: The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2006, 80:5074-5077.
• [21]Mothé BR, Weinfurter J, Wang C, Rehrauer W, Wilson N, Allen TM, Allison DB, Watkins DI: Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 2003, 77:2736-2740.
• [22]Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG: Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005, 41:1326-1332.
• [23]Van Rompay KKA, Singh R, Brignolo L, Lawson JR, Schmidt KA, Pahar B, Canfield DR, Tarara RP, Bischofberger N, Marthas M: The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. JAIDS 2004, 36:900-914.
• [24]Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
• [25]Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH: Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006, 203:2223-2227.
• [26]Magierowska M, Bernardin F, Garg S, Staprans S, Miller MD, Van Rompay KKA, Delwart EL: Highly uneven distribution of PMPA selected SIV drug resistance genotypes in different anatomical sites of rhesus macaques. J Virol 2004, 78:2434-2444.
• [27]Rong L, Perelson AS: Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol 2009, 260:308-331.
• [28]Villinger F, Brice GT, Mayne AE, Bostik P, Mori K, June CH, Ansari AA: Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ T cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 2002, 99:590-599.
• [29]Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyeri FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-339.
• [30]Abel K, Compton L, Rourke T, Montefiori D, Lu D, Rothaeusler K, Fritts L, Bost K, Miller CJ: Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 2003, 77:3099-3118.
• [31]Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, Patel V, von Gegerfelt AS, Montefiori DC, Venzon DJ, et al.: DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009, 106:15831-15836.
• [32]Grant PM, Taylor J, Nevins AB, Calvez V, Marcelin AG, Wirden M, Zolopa AR: Antiviral Activity of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase: An International Cohort Analysis. Antimicrob Agents Chemother 2010, 54:1520-1525.
• [33]Chappell BJ, Margot NA, Miller MD: Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. AIDS 2007, 21:761-763.
• [34]McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD: Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2004, 37:1340-1350.
• [35]Saksena NK, Rodes B, Wang B, Soriano V: Elite HIV controllers: myth or reality? AIDS Rev 2007, 9:195-207.
• [36]Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K: Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 2006, 80:9217-9225.
• [37]Genesca M, Skinner PJ, Hong JJ, Li J, Lu D, McChesney MB, Miller CJ: With minimal systemic T-cell expansion, CD8+ T Cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 2008, 82:11181-11196.
• [38]Van Rompay KKA, Singh RP, Heneine W, Johnson JA, Montefiori DC, Bischofberger N, Marthas ML: Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol 2006, 80:6399-6410.
• [39]Van Rompay KKA, Dailey PJ, Tarara RP, Canfield DR, Aguirre NL, Cherrington JM, Lamy PD, Bischofberger N, Pedersen NC, Marthas ML: Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1999, 73:2947-2955.
• [40]Hel Z, Venzon D, Poudyal M, Tsai W-P, Giuliani L, Woodward R, Chougnet C, Shearer G, Altman JD, Watkins DW, et al.: Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000, 6:1140-1146.
• [41]Fuller DH, Rajakumar PA, Wu MS, McMahon CW, Shipley T, Fuller JT, Bazmi A, Trichel AM, Allen TM, Mothe B, et al.: DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology 2006, 348:200-215.
• [42]Rosenwirth B, ten Haaft P, Bogers WMJM, Nieuwenhuis IG, Niphuis H, Kuhn E-M, Bischofberger N, Heeney JL, Überla K: Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000, 74:1704-1711.
• [43]North TW, Van Rompay KKA, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF: Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 2005, 79:7349-7354.
• [44]Rosenwirth B, Bogers WM, Nieuwenhuis IG, Haaft PT, Niphuis H, Kuhn EM, Bischofberger N, Erfle V, Sutter G, Berglund P, et al.: An anti-HIV strategy combining chemotherapy and therapeutic vaccination. J Med Primatol 1999, 28:195-205.
• [45]Spring M, Stahl-Hennig C, Stolte N, Bischofberger N, Heeney J, ten Haaft P, Tenner-Ràcz K, Ràcz P, Lorenzen D, Hunsmann G, Dittmer U: Enhanced cellular immune responses and reduced CD8+ lymphocytes apoptosis in acutely SIV-infected rhesus macaques after short-term antiretroviral treatment. Virology 2001, 279:221-231.
• [46]Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Li Z, Adany I, et al.: Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment of SHIVKU2 infection of rhesus macaques. Virology 2000, 277:306-315.
• [47]Taber R, Rajakumar PA, Fuller DH, Trichel AM, Dowling P, Meleason D, Amedee A, Murphey-Corb M: Effects of monotherapy with (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) on the evolution of a primary Simian immunodeficiency virus (SIV) isolate. Virology 2006, 354:116-131.
• [48]Tsai C-C, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ: Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection. AIDS Res Hum Retrovir 1997, 13:707-712.
• [49]Tryniszewska E, Nacsa J, Lewis MG, Silvera P, Montefiori D, Venzon D, Hel Z, Parks RW, Moniuszko M, Tartaglia J, et al.: Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. JI 2002, 169:5347-5357.
• [50]Uberla K, Rosenwirth B, Ten Haaft P, Heeney J, Sutter G, Erfle V: Therapeutic immunization with Modified Vaccinia Virus Ankara (MVA) vaccines in SIV-infected rhesus monkeys undergoing antiretroviral therapy. J Med Primatol 2007, 36:2-9.
• [51]Vagenas P, Williams VG, Piatak M, Bess JW, Lifson JD, Blanchard JL, Gettie A, Robbiani M: Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239. J Acquir Immune Defic Syndr 2009, 52:433-442.
• [52]Zur Megede J, Sanders-Beer B, Silvera P, Golightly D, Bowlsbey A, Hebblewaite D, Sites D, Nieves-Duran L, Srivastava R, Otten GR, et al.: A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res Hum Retrovir 2008, 24:1103-1116.
• [53]Kubo M, Nishimura Y, Shingai M, Lee W, Brenchley J, Lafont B, Buckler-White A, Igarashi T, Martin MA: Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease. J Virol 2009, 83:7099-7108.
• [54]Cervasi B, Paiardini M, Serafini S, Fraternale A, Menotta M, Engram J, Lawson B, Staprans SI, Piedimonte G, Perno CF, et al.: Administration of fludarabine-loaded autologous red blood cells in simian immunodeficiency virus-infected sooty mangabeys depletes pSTAT-1-expressing macrophages and delays the rebound of viremia after suspension of antiretroviral therapy. J Virol 2006, 80:10335-10345.
• [55]Ho DD: Toward HIV eradication or remission: the tasks ahead. Science 1998, 280:1866-1867.
• [56]Harrigan PR, Whaley M, Montaner JSG: Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 13:F59-F62.
• [57]Chun TW, Davey RTJ, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature 1999, 401:874-875.
• [58]Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD: It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell Counts >250 cells/microL. J Acquir Immune Defic Syndr 2004, 37:1351-1357.
• [59]Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C: Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010, 24:1598-1601.
• [60]Deeks SG, Martin JN, Sinclair E, Harris J, Neilands TB, Maecker HT, Hagos E, Wrin T, Petropoulos CJ, Bredt B, McCune JM: Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004, 189:312-321.
• [61]Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin A, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C: Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005, 19:25-33.
• [62]Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR: Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005, 41:236-242.
• [63]Eron JJ, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VA: Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004, 37:1581-1583.
• [64]Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN: Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005, 192:1537-1544.
• [65]Van Rompay KKA, Marthas ML, Bischofberger N: Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion. Antivir Res 2004, 63:133-138.
• [66]Potmesil P, Holy A, Kmonickova E, Krizkova J, Zidek Z: Acyclic nucleoside phosphonate antivirals activate gene expression of monocyte chemotactic protein 1 and 3. J Biomed Sci 2007, 14:59-66.
• [67]National Research Council: Guide for the care and use of laboratory animals. National Academy Press, Washington, D. C.; 1996.
• [68]Shacklett BL, Cox CA, Sandberg JK, Stollman NH, Jacobson MA, Nixon DF: Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol 2003, 77:5621-5631.
• [69]Cline AN, Bess JW, Piatak M, Lifson JD: Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 2005, 34:303-312.
• [70]Venneti S, Bonneh-Barkay D, Lopresti BJ, Bissel SJ, Wang G, Mathis CA, Piatak M, Lifson JD, Nyaundi JO, Murphey-Corb M, Wiley CA: Longitudinal in vivo positron emission tomography imaging of infected and activated brain macrophages in a macaque model of human immunodeficiency virus encephalitis correlates with central and peripheral markers of encephalitis and areas of synaptic degeneration. Am J Pathol 2008, 172:1603-1616.
• [71]Johnson JA, Van Rompay KKA, Delwart E, Heneine W: A sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase. AIDS Res Hum Retrovir 2006, 22:912-916.
• [72]Kaizu M, Borchardt GJ, Glidden CE, Fisk DL, Loffredo JT, Watkins DI, Rehrauer WM: Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes. Immunogenetics 2007, 59:693-703.
• [73]Van Rompay KK, Abel K, Earl P, Kozlowski PA, Easlick J, Moore J, Buonocore-Buzzelli L, Schmidt KA, Wilson RL, Simon I, et al.: Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 2010, 28:1481-1492.
• [74]Montefiori DC: Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In Current Protocols in Immunology. Edited by Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, Coico R. John Wiley & Sons; 2004:12.11.11-12.11.15.
• [75]Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al.: Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.